QSAM Biosciences Receives Japanese Patent for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam®
QSAM Biosciences has announced a significant milestone with the Japan Patent Office granting a patent for its treatment technology utilizing Samarium-153-DOTMP (CycloSam®) for bone cancer in children and adults. This patent enhances QSAM's growing intellectual property portfolio, now totaling 14 patents across three families. The patented method improves dosing regimens by reducing impurities, potentially increasing clinical efficacy in treating both primary and metastatic bone cancers. QSAM is currently advancing its FDA-cleared Phase 1 clinical trial for CycloSam®.
- Patent granted in Japan for Samarium-153 technology protects potential market for CycloSam®.
- Intellectual property portfolio expanded to 14 patents, enhancing commercial prospects.
- Potential for improved clinical outcomes with reduced impurities in dosing regimens.
- Active Phase 1 clinical trial recruiting patients, indicating progress in drug development.
- None.
Austin, TX, April 12, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®), for the treatment of cancer and related diseases, announced today that the Japan Patent Office has granted a key patent that protects the use of “lower specific activity” Samarium-153 in conjunction with the treatment of bone cancer in children and adults.
This patent covers within the Japanese market the “high purity therapeutic bone agents” technology exclusively licensed to QSAM on a worldwide basis, and relates to the novel manner in which the Samarium-153 used in CycloSam® is produced. That process reduces long-lived impurities -- namely Europium-154 -- which may allow for higher and multiple dosing regimens in the treatment of different types of bone cancer, including cancer that has metastasized from the lung, breast or prostate. Those types of metastasized bone cancer are the subject of QSAM’s current FDA-cleared Phase 1 clinical trial, which has already begun recruiting and screening patients. Management believes that multi-dosing regimens may be the key to CycloSam® being able to successfully treat bone tumors, and is advancing it clinical trials toward that goal.
“This issuance marks our third granted patent in Japan, and further expands our IP estate consisting of 14 patents among 3 distinct patent families. This additional IP protection broadens our potential commercial market internationally for what we believe may be a breakthrough therapy for both primary and secondary forms of bone cancer,” stated Douglas R. Baum, CEO and co-founder of the Company.
About QSAM Biosciences
QSAM Biosciences, Inc. is developing next-generation nuclear medicines for the treatment of cancer and related diseases. QSAM’s initial technology, CycloSam® (Samarium-153 DOTMP), is a clinical-stage bone targeting radiopharmaceutical developed by IsoTherapeutics Group LLC, pioneers in the nuclear medicine space who also developed the FDA-approved Quadramet® (Samarium-153 EDTMP) radiopharmaceutical product, which is indicated for pain palliation. QSAM is led by an experienced executive team and Board of Directors that have completed numerous FDA approvals and multiple successful biotech exits.
CycloSam® has demonstrated preliminary safety and efficacy in animal studies and a single patient FDA-cleared human trial performed in 2020 at the Cleveland Clinic. This nuclear technology uses low specific activity Samarium-153 (resulting in far less europium impurity) and DOTMP, a chelator which is believed to reduce or eliminate off-target migration and targets sites of high bone turn over making it, in management’s opinion, an ideal agent to treat primary and secondary bone cancers. Since CycloSam® delivers targeted radiation selectively to the skeletal system, it is also believed to be a great candidate for effectiveness trials in bone marrow ablation as pre-conditioning for bone marrow transplantation, and in procedures to reduce external beam radiation to bone tumors. This multi-patented drug candidate utilizes a radioisotope approved by the FDA previously combined with a novel chelant that has demonstrated preliminary increased efficacy and decreased side effects in animal models and veterinary treatment of bone cancer in dogs. Further, CycloSam® utilizes a streamlined, just-in-time manufacturing process that is already in place. Given these factors, management believes there is a strong pathway to commercialization for CycloSam®.
Legal Notice Regarding Forward-Looking Statements: This news release contains "Forward-looking Statements". These statements relate to future events or our future financial performance. These statements are only predictions and may differ materially from actual future results or events. We disclaim any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise. There are important risk factors that could cause actual results to differ from those contained in forward-looking statements, including, but not limited to our ability to fully commercialize our technology, risks associated with changes in general economic and business conditions, regulatory risks, clinical trial risks, early stage versus late stage product safety and efficacy, actions of our competitors, the extent to which we are able to develop new products and markets, the time and expense involved in such development activities, the ability to secure additional financing, the ability to consummate acquisitions and ultimately integrate them, the level of demand and market acceptance of our products, and changes in our business strategies. This is not an offering of securities and securities may not be offered or sold absent registration or an applicable exemption from the registration requirements.
Contact
Investors:
Jason Nelson
CORE IR
ir@qsambio.com
516 222 2560
Media:
Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com
FAQ
What is the significance of the patent granted to QSAM Biosciences on April 12, 2022?
How many patents does QSAM Biosciences currently hold?
What is CycloSam® and its relevance for QSAM Biosciences?
What types of cancer is QSAM targeting with CycloSam®?
What phase is QSAM's current clinical trial for CycloSam®?
